Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Metabolic checkpoints in neurodegenerative T helper 17 (TH17) and neuroregenerative regulatory T (Treg) cells as new therapeutic targets for multiple sclerosis.

Shen H, Bonner JA, Shi LZ.

Neural Regen Res. 2020 Feb;15(2):267-269. doi: 10.4103/1673-5374.265552. No abstract available.

2.

Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.

Mell LK, Shen H, Nguyen-Tân PF, Rosenthal DI, Zakeri K, Vitzthum LK, Frank SJ, Schiff PB, Trotti AM 3rd, Bonner JA, Jones CU, Yom SS, Thorstad WL, Wong SJ, Shenouda G, Ridge JA, Zhang QE, Le QT.

Clin Cancer Res. 2019 Dec 1;25(23):7078-7088. doi: 10.1158/1078-0432.CCR-19-1832. Epub 2019 Aug 16.

PMID:
31420360
3.

Differential escape mechanisms in cetuximab-resistant head and neck cancer cells.

Willey CD, Anderson JC, Trummell HQ, Naji F, de Wijn R, Yang ES, Bredel M, Thudi NK, Bonner JA.

Biochem Biophys Res Commun. 2019 Sep 10;517(1):36-42. doi: 10.1016/j.bbrc.2019.06.159. Epub 2019 Jul 13.

PMID:
31311651
4.

Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma.

Eustace NJ, Anderson JC, Langford CP, Trummell HQ, Hicks PH, Jarboe JS, Mobley JA, Hjelmeland AB, Hackney JR, Pedersen RT, Cosby K, Gillespie GY, Bonner JA, Willey CD.

Int J Oncol. 2019 Jun;54(6):2039-2053. doi: 10.3892/ijo.2019.4766. Epub 2019 Mar 29.

5.

A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck.

Ward MC, Lee NY, Caudell JJ, Zajichek A, Awan MJ, Koyfman SA, Dunlap NE, Zakem SJ, Hassanzadeh C, Marcrom S, Boggs DH, Isrow D, Vargo JA, Heron DE, Siddiqui F, Bonner JA, Beitler JJ, Yao M, Trotti AM, Riaz N; Multi-Institution Re-Irradiation (MIRI) Collaborative.

Oral Oncol. 2019 Mar;90:80-86. doi: 10.1016/j.oraloncology.2019.01.022. Epub 2019 Feb 8.

PMID:
30846182
6.

Gender, Professional Experiences, and Personal Characteristics of Academic Radiation Oncology Chairs: Data to Inform the Pipeline for the 21st Century.

Beeler WH, Griffith KA, Jones RD, Chapman CH, Holliday EB, Lalani N, Wilson E, Bonner JA, Formenti SC, Hahn SM, Kalnicki S, Liu FF, Movsas B, Thomas CR Jr, Jagsi R.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):979-986. doi: 10.1016/j.ijrobp.2019.01.074. Epub 2019 Jan 23.

PMID:
30684662
7.

In Regard to Bossi et al.

Fakhry C, Nguyen-Tân PF, Lambert L, Rosenthal DI, Weber RS, Gillison ML, Trotti AM 3rd, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):669-670. doi: 10.1016/j.ijrobp.2018.06.020. No abstract available.

PMID:
30238902
8.

Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations.

Jones RD, Chapman CH, Holliday EB, Lalani N, Wilson E, Bonner JA, Movsas B, Kalnicki S, Formenti SC, Thomas CR Jr, Hahn SM, Liu FF, Jagsi R; Society of Chairs of Academic Radiation Oncology Programs (SCAROP).

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):30-45. doi: 10.1016/j.ijrobp.2018.01.012. Epub 2018 Jan 9.

PMID:
29477292
9.

Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis.

Caudell JJ, Ward MC, Riaz N, Zakem SJ, Awan MJ, Dunlap NE, Isrow D, Hassanzadeh C, Vargo JA, Heron DE, Marcrom S, Boggs DH, Reddy CA, Dault J, Bonner JA, Higgins KA, Beitler JJ, Koyfman SA, Machtay M, Yao M, Trotti AM, Siddiqui F, Lee NY; Multi-Institution Reirradiation (MIRI) Collaborative.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):606-617. doi: 10.1016/j.ijrobp.2017.11.036. Epub 2017 Dec 1.

PMID:
29413274
10.

Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance).

Major-Elechi BT, Novotny PJ, Singh JA, Bonner JA, Dueck AC, Sargent DJ, Grothey A, Sloan JA.

Int J Stat Med Res. 2018;7(4):137-146. doi: 10.6000/1929-6029.2018.07.04.4. Epub 2018 Nov 16.

11.

ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.

Chakraborty A, Dorsett KA, Trummell HQ, Yang ES, Oliver PG, Bonner JA, Buchsbaum DJ, Bellis SL.

J Biol Chem. 2018 Jan 19;293(3):984-994. doi: 10.1074/jbc.M117.808584. Epub 2017 Nov 30.

12.

A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer.

Vargo JA, Ward MC, Caudell JJ, Riaz N, Dunlap NE, Isrow D, Zakem SJ, Dault J, Awan MJ, Higgins KA, Hassanadeh C, Beitler JJ, Reddy CA, Marcrom S, Boggs DH, Bonner JA, Yao M, Machtay M, Siddiqui F, Trotti AM, Lee NY, Koyfman SA, Ferris RL, Heron DE.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):595-605. doi: 10.1016/j.ijrobp.2017.04.017. Epub 2017 Apr 24.

PMID:
28899556
13.

Emotional Intelligence and Burnout in Academic Radiation Oncology Chairs.

Holliday EB, Bonner JA, Formenti SC, Hahn SM, Kalnicki S, Liu FF, Movsas B, Fuller CD, Thomas CR Jr.

J Healthc Manag. 2017 Sep/Oct;62(5):302-313. doi: 10.1097/JHM-D-16-00001.

PMID:
28885530
14.

Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative.

Ward MC, Riaz N, Caudell JJ, Dunlap NE, Isrow D, Zakem SJ, Dault J, Awan MJ, Vargo JA, Heron DE, Higgins KA, Beitler JJ, Marcrom S, Boggs DH, Hassanzadeh C, Reddy CA, Bonner JA, Yao M, Machtay M, Siddiqui F, Trotti AM, Lee NY, Koyfman SA; Multi-Institution Reirradiation (MIRI) Collaborative.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):586-594. doi: 10.1016/j.ijrobp.2017.06.012. Epub 2017 Jun 17.

PMID:
28865925
15.

Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.

Fakhry C, Zhang Q, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM 3rd, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML.

J Clin Oncol. 2017 Dec 20;35(36):4057-4065. doi: 10.1200/JCO.2016.72.0748. Epub 2017 Aug 4.

16.

p16, HPV, and Cetuximab: What Is the Evidence?

Bonner JA, Mesia R, Giralt J, Psyrri A, Keilholz U, Rosenthal DI, Beier F, Schulten J, Vermorken JB.

Oncologist. 2017 Jul;22(7):811-822. doi: 10.1634/theoncologist.2016-0433. Epub 2017 May 18. Review.

17.

Cetuximab and Radiotherapy in Laryngeal Preservanion-Reply.

Bonner JA, Chin S, Spencer S.

JAMA Otolaryngol Head Neck Surg. 2017 May 1;143(5):526. doi: 10.1001/jamaoto.2016.3809. No abstract available.

PMID:
28006051
18.

Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.

Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Konski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, Shenouda G, Matthiesen C, Le QT, Bruner D.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):687-699. doi: 10.1016/j.ijrobp.2016.08.003. Epub 2016 Aug 12.

19.

Correction: Kinomic Profiling of Electromagnetic Navigational Bronchoscopy Specimens: A New Approach for Personalized Medicine.

Anderson JC, Minnich DJ, Dobelbower MC, Denton AJ, Dussaq AM, Gilbert AN, Rohrbach TD, Arafat W, Welaya K, Bonner JA, Willey CD.

PLoS One. 2016 Aug 24;11(8):e0161986. doi: 10.1371/journal.pone.0161986. eCollection 2016.

20.

Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.

Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D, Raben D, Liu J, Schulten J, Ang KK, Rosenthal DI.

Eur J Cancer. 2016 Sep;64:1-11. doi: 10.1016/j.ejca.2016.05.008. Epub 2016 Jun 17.

21.
22.

Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition.

Bonner JA, Trummell HQ, Bonner AB, Willey CD, Bredel M, Yang ES.

BMC Cancer. 2015 Oct 12;15:673. doi: 10.1186/s12885-015-1679-x.

23.

DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.

Weaver AN, Cooper TS, Rodriguez M, Trummell HQ, Bonner JA, Rosenthal EL, Yang ES.

Oncotarget. 2015 Sep 29;6(29):26995-7007. doi: 10.18632/oncotarget.4863.

24.

Society of Chairs of Academic Radiation Oncology Programs-Endorsed Radiation Oncology Department Review Process.

Thomas CR Jr, Bonner JA, Hahn SM, Lawrence TS, Liu FF, Formenti SC; Society of Chairs of Academic Radiation Oncology Programs.

Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):536-9. doi: 10.1016/j.ijrobp.2015.02.040. No abstract available.

PMID:
26068488
25.

Kinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicine.

Anderson JC, Minnich DJ, Dobelbower MC, Denton AJ, Dussaq AM, Gilbert AN, Rohrbach TD, Arafat W, Welaya K, Bonner JA, Willey CD.

PLoS One. 2014 Dec 30;9(12):e116388. doi: 10.1371/journal.pone.0116388. eCollection 2014. Erratum in: PLoS One. 2016;11(8):e0161986.

26.

Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity.

Rohrbach TD, Jarboe JS, Anderson JC, Trummell HQ, Hicks PH, Weaver AN, Yang ES, Oster RA, Deshane JS, Steele C, Siegal GP, Bonner JA, Willey CD.

Int J Oncol. 2015 Mar;46(3):1079-88. doi: 10.3892/ijo.2014.2799. Epub 2014 Dec 17.

PMID:
25524703
27.

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS.

J Clin Oncol. 2014 Sep 20;32(27):2940-50.

28.

Pazopanib combined with radiation: in vivo model of interaction.

Meredith RF, Raisch KP, Bonner JA, Buchsbaum DJ, Grizzle WE, Li Y, Spencer SA.

Cancer Biother Radiopharm. 2014 Aug;29(6):247-50. doi: 10.1089/cbr.2013.1583. Epub 2014 Jun 19.

PMID:
24945464
29.

Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology.

Kong FS, Cuneo KC, Wang L, Bonner JA, Gaspar LE, Komaki R, Sun A, Morris DE, Sandler HM, Movsas B.

Pract Radiat Oncol. 2014 Mar-Apr;4(2):e133-e141. doi: 10.1016/j.prro.2013.05.002. Epub 2013 Jun 12.

PMID:
24890359
30.

Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.

Anderson JC, Duarte CW, Welaya K, Rohrbach TD, Bredel M, Yang ES, Choradia NV, Thottassery JV, Yancey Gillespie G, Bonner JA, Willey CD.

Radiother Oncol. 2014 Jun;111(3):468-74. doi: 10.1016/j.radonc.2014.04.010. Epub 2014 May 8.

31.

Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute.

Prendergast BM, Dobelbower MC, Bonner JA, Popple RA, Baden CJ, Minnich DJ, Cerfolio RJ, Spencer SA, Fiveash JB.

Radiat Oncol. 2013 Nov 20;8:273. doi: 10.1186/1748-717X-8-273.

32.

Burnout in United States academic chairs of radiation oncology programs.

Kusano AS, Thomas CR Jr, Bonner JA, DeWeese TL, Formenti SC, Hahn SM, Lawrence TS, Mittal BB.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):363-8. doi: 10.1016/j.ijrobp.2013.09.027. Epub 2013 Nov 1.

PMID:
24189126
33.

Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy.

Prendergast BM, Fiveash JB, Popple RA, Clark GM, Thomas EM, Minnich DJ, Jacob R, Spencer SA, Bonner JA, Dobelbower MC.

J Appl Clin Med Phys. 2013 May 6;14(3):4126. doi: 10.1120/jacmp.v14i3.4126.

34.

Patterns of prophylactic gastrostomy tube placement in head and neck cancer patients: a consideration of the significance of social support and practice variation.

Locher JL, Bonner JA, Carroll WR, Caudell JJ, Allison JJ, Kilgore ML, Ritchie CS, Tajeu GS, Yuan Y, Roth DL.

Laryngoscope. 2013 Aug;123(8):1918-25. doi: 10.1002/lary.24022. Epub 2013 Feb 7.

35.

Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies.

Wagner MM, Curé JK, Caudell JJ, Spencer SA, Nabell LM, Carroll WR, Bonner JA.

Radiat Oncol. 2012 Dec 21;7:219. doi: 10.1186/1748-717X-7-219.

36.

HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.

Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES.

Cancer Res. 2012 Sep 15;72(18):4796-806. doi: 10.1158/0008-5472.CAN-12-1287.

37.

Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, Behrendt K, Koch R, Bishop JF, Dische S, Arriagada R, De Ruysscher D, Pignon JP.

J Clin Oncol. 2012 Aug 1;30(22):2788-97. doi: 10.1200/JCO.2012.41.6677. Epub 2012 Jul 2.

38.

MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma.

Jarboe JS, Anderson JC, Duarte CW, Mehta T, Nowsheen S, Hicks PH, Whitley AC, Rohrbach TD, McCubrey RO, Chiu S, Burleson TM, Bonner JA, Gillespie GY, Yang ES, Willey CD.

Clin Cancer Res. 2012 Jun 1;18(11):3030-41. doi: 10.1158/1078-0432.CCR-11-3091. Epub 2012 May 22.

39.

Kinomic profiling approach identifies Trk as a novel radiation modulator.

Jarboe JS, Jaboin JJ, Anderson JC, Nowsheen S, Stanley JA, Naji F, Ruijtenbeek R, Tu T, Hallahan DE, Yang ES, Bonner JA, Willey CD.

Radiother Oncol. 2012 Jun;103(3):380-7. doi: 10.1016/j.radonc.2012.03.014. Epub 2012 May 5.

40.

Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer.

Dragovic AF, Caudell JJ, Spencer SA, Carroll WR, Nabell LA, Bonner JA.

Head Neck. 2013 Mar;35(3):381-7. doi: 10.1002/hed.22977. Epub 2012 Mar 9.

PMID:
22407986
41.

Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors.

Mills CN, Nowsheen S, Bonner JA, Yang ES.

Front Mol Neurosci. 2011 Nov 25;4:47. doi: 10.3389/fnmol.2011.00047. eCollection 2011.

42.

Small-cell lung cancer: prognostic factors and changing treatment over 15 years.

Gaspar LE, McNamara EJ, Gay EG, Putnam JB, Crawford J, Herbst RS, Bonner JA.

Clin Lung Cancer. 2012 Mar;13(2):115-22. doi: 10.1016/j.cllc.2011.05.008. Epub 2011 Oct 14.

PMID:
22000695
43.

Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer.

Dragovic AF, Bonner JA, Spencer SA, Nabell LM, Carroll WR, Caudell JJ.

Head Neck. 2011 Nov;33(11):1551-6. doi: 10.1002/hed.21634. Epub 2010 Dec 9.

PMID:
21990218
44.

Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.

Nowsheen S, Bonner JA, Lobuglio AF, Trummell H, Whitley AC, Dobelbower MC, Yang ES.

PLoS One. 2011;6(8):e24148. doi: 10.1371/journal.pone.0024148. Epub 2011 Aug 30.

45.

Dosimetric impact of target definitions on normal structures in head and neck cancer.

Monaghan MT, Bonner JA, Schaner PE, Caudell JJ.

Head Neck Oncol. 2011 Aug 11;3:34. doi: 10.1186/1758-3284-3-34.

46.

Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.

Bonner JA, Willey CD, Yang ES, Dobelbower MC, Sanford LL, Bright SJ, Buchsbaum DJ, Raisch KP.

Radiother Oncol. 2011 Oct;101(1):183-9. doi: 10.1016/j.radonc.2011.05.083. Epub 2011 Jun 30.

PMID:
21722984
47.

The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.

Nowsheen S, Bonner JA, Yang ES.

Radiother Oncol. 2011 Jun;99(3):331-8. doi: 10.1016/j.radonc.2011.05.084. Epub 2011 Jun 28.

48.

Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.

Bonner JA, Yang ES, Trummell HQ, Nowsheen S, Willey CD, Raisch KP.

Radiother Oncol. 2011 Jun;99(3):339-43. doi: 10.1016/j.radonc.2011.05.070. Epub 2011 Jun 23.

PMID:
21704410
49.

Gastrostomy tube placement and use in patients with head and neck cancer.

Locher JL, Bonner JA, Carroll WR, Caudell JJ, Kilgore ML, Ritchie CS, Roth DL, Tajeu GS, Yuan Y, Allison JJ.

Head Neck. 2012 Mar;34(3):422-8. doi: 10.1002/hed.21753. Epub 2011 May 20.

PMID:
21604317
50.

Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients.

Dean NR, Sweeny L, Harari PM, Bonner JA, Jones V, Clemons L, Geye H, Rosenthal EL.

J Wound Care. 2011 Apr;20(4):166-70.

Supplemental Content

Loading ...
Support Center